RT Journal Article
T1 EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.
A1 Chaparro, María
A1 Barreiro-de Acosta, Manuel
A1 Benítez, José Manuel
A1 Cabriada, José Luis
A1 Casanova, María José
A1 Ceballos, Daniel
A1 Esteve, María
A1 Fernández, Hipólito
A1 Ginard, Daniel
A1 Gomollón, Fernando
A1 Lorente, Rufo
A1 Nos, Pilar
A1 Riestra, Sabino
A1 Rivero, Montserrat
A1 Robledo, Pilar
A1 Rodríguez, Cristina
A1 Sicilia, Beatriz
A1 Torrella, Emilio
A1 Garre, Ana
A1 García-Esquinas, Esther
A1 Rodríguez-Artalejo, Fernando
A1 Gisbert, Javier P
A1 EpidemIBD study group of GETECCU, 
K1 Crohn’s disease
K1 epidemiology
K1 incidence
K1 inflammatory bowel disease
K1 ulcerative colitis
AB Inflammatory bowel disease (IBD) is associated with a considerable burden to the patient and society. However, current data on IBD incidence and burden are limited because of the paucity of nationwide epidemiological studies, heterogeneous designs, and a low number of participating centers and sample size. The EpidemIBD study is a large-scale investigation to provide an accurate assessment of the incidence of IBD in Spain, as well as treatment patterns and outcomes. This multicenter, population-based incidence cohort study included patients aged >18 years with IBD (Crohn's disease, ulcerative colitis, or unclassified IBD) diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population. Each participating patient will attend 10 clinic visits during 5 years of follow up. Demographic data, IBD characteristics and family history, complications, treatments, surgeries, and hospital admissions will be recorded. The EpidemIBD study is the first large-scale nationwide study to investigate the incidence of IBD in Spain. Enrollment is now completed and 3627 patients are currently being followed up. The study has been designed to overcome many of the limitations of previous European studies into IBD incidence by prospectively recruiting a large number of patients from all regions of Spain. In addition to epidemiological information about the burden of IBD, the 5-year follow-up period will also provide information on treatment patterns, and the natural history and financial burden of IBD.
SN 1756-283X
YR 2019
FD 2019-05-21
LK https://hdl.handle.net/10668/28274
UL https://hdl.handle.net/10668/28274
LA en
DS RISalud
RD Apr 7, 2025